Guideline
doi: 10.1212/wnl.58.2.169.
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
- PMID: 11805241
- DOI: 10.1212/wnl.58.2.169
Item in Clipboard
Guideline
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Neurology.
.
Erratum in
- Neurology 2002 Aug13;59(3):480
No abstract available
Comment in
-
Disease modifying therapies in multiple sclerosis.Neurology. 2002 Aug 13;59(3):471-2; author reply 472-3. doi: 10.1212/wnl.59.3.471. Neurology. 2002. PMID: 12177396 No abstract available.
-
Disease modifying therapies in multiple sclerosis.Neurology. 2002 Aug 13;59(3):472; author reply 472-3. Neurology. 2002. PMID: 12184316 No abstract available.
Similar articles
-
Current disease-modifying therapies in multiple sclerosis.Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138. Semin Neurol. 2003. PMID: 12894379 Review.
-
Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?Clin Neuropharmacol. 2003 Jan-Feb;26(1):28-37. doi: 10.1097/00002826-200301000-00007. Clin Neuropharmacol. 2003. PMID: 12567162 Review. No abstract available.
-
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.Health Technol Assess. 2000;4(9):i-iv, 1-101. Health Technol Assess. 2000. PMID: 10944743 Review. No abstract available.
-
Immunologic therapy for relapsing-remitting multiple sclerosis.Curr Neurol Neurosci Rep. 2001 May;1(3):277-85. doi: 10.1007/s11910-001-0031-9. Curr Neurol Neurosci Rep. 2001. PMID: 11898530 Review.
-
Immunologic therapy for secondary and primary progressive multiple sclerosis.Curr Neurol Neurosci Rep. 2001 May;1(3):286-93. doi: 10.1007/s11910-001-0032-8. Curr Neurol Neurosci Rep. 2001. PMID: 11898531 Review.
Cited by
-
Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey.Neurol Clin Pract. 2025 Feb;15(1):e200376. doi: 10.1212/CPJ.0000000000200376. Epub 2024 Oct 9. Neurol Clin Pract. 2025. PMID: 39399557
-
Orchestrating Stress Responses in Multiple Sclerosis: A Role for Astrocytic IFNγ Signaling.Int J Mol Sci. 2024 Jul 9;25(14):7524. doi: 10.3390/ijms25147524. Int J Mol Sci. 2024. PMID: 39062765 Free PMC article. Review.
-
Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment.Hosp Pharm. 2024 Aug;59(4):476-484. doi: 10.1177/00185787241232615. Epub 2024 Feb 15. Hosp Pharm. 2024. PMID: 38919754
-
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?Curr Neuropharmacol. 2024;22(8):1286-1326. doi: 10.2174/1570159X22666240124114126. Curr Neuropharmacol. 2024. PMID: 38275058 Free PMC article. Review.
-
Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1.J Neuroinflammation. 2023 Oct 12;20(1):234. doi: 10.1186/s12974-023-02917-4. J Neuroinflammation. 2023. PMID: 37828609 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
